- Home
- AYTU vs BCTX Comparison
AYTU vs BCTX Comparison
Compare AYTU & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- BCTX
- Stock Information
- Founded
- AYTU N/A
- BCTX 2014
- Country
- AYTU United States
- BCTX Canada
- Employees
- AYTU N/A
- BCTX N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- AYTU Health Care
- BCTX Health Care
- Exchange
- AYTU Nasdaq
- BCTX Nasdaq
- Market Cap
- AYTU 18.8M
- BCTX 19.0M
- IPO Year
- AYTU N/A
- BCTX N/A
- Fundamental
- Price
- AYTU $2.37
- BCTX N/A
- Analyst Decision
- AYTU Strong Buy
- BCTX Strong Buy
- Analyst Count
- AYTU 3
- BCTX 1
- Target Price
- AYTU $9.17
- BCTX $40.00
- AVG Volume (30 Days)
- AYTU 393.1K
- BCTX 77.8K
- Earning Date
- AYTU 11-12-2025
- BCTX 10-28-2025
- Dividend Yield
- AYTU N/A
- BCTX N/A
- EPS Growth
- AYTU N/A
- BCTX N/A
- EPS
- AYTU N/A
- BCTX N/A
- Revenue
- AYTU $66,382,000.00
- BCTX N/A
- Revenue This Year
- AYTU N/A
- BCTX N/A
- Revenue Next Year
- AYTU $19.03
- BCTX N/A
- P/E Ratio
- AYTU N/A
- BCTX N/A
- Revenue Growth
- AYTU 1.84
- BCTX N/A
- 52 Week Low
- AYTU $0.95
- BCTX $6.00
- 52 Week High
- AYTU $2.82
- BCTX $190.50
- Technical
- Relative Strength Index (RSI)
- AYTU 57.62
- BCTX 84.38
- Support Level
- AYTU $1.65
- BCTX $12.50
- Resistance Level
- AYTU $1.98
- BCTX $13.60
- Average True Range (ATR)
- AYTU 0.16
- BCTX 0.67
- MACD
- AYTU 0.03
- BCTX 0.06
- Stochastic Oscillator
- AYTU 70.30
- BCTX 84.88
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.